Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2018 | Allogeneic therapy for the treatment of refractory hematological malignancies

Mohamad Mohty • 11 May 2018
EBMT 2018
Acute Myeloid Leukemia

There has been an increase in the number of patients with refractory hematological malignancies being referred to transplant centers, although previously, treatment was limited for refractory conditions. In this talk, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, alludes to the optimism regarding allogeneic therapy for patients with refractory hematological malignancies. Talking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Prof. Mohty discusses the potential candidates for allogeneic transplantation.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Mohamad Mohty

CERVINO trial results and the potential role of etentamig in multiple myeloma
1:19
CERVINO trial results and the potential role of etentamig in multiple myeloma
Mohamad Mohty • 24 Sep 2026
IMS 2026 highlights: evolving multiple myeloma treatment and the path toward cure
7:00
IMS 2026 highlights: evolving multiple myeloma treatment and the path toward cure
Mohamad Mohty • 24 Sep 2026
Transitioning bispecifics into community care for myeloma: recently published guidelines
5:44
Transitioning bispecifics into community care for myeloma: recently published guidelines
Mohamad Mohty • 13 Jun 2026
Key highlights from COMy 2026: quadruplet regimens, CAR-T, bispecifics, trispecifics, and more
8:13
Key highlights from COMy 2026: quadruplet regimens, CAR-T, bispecifics, trispecifics, and more
Mohamad Mohty • 15 May 2026

Related Videos

Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
8:41
Dapolsertib in AML: results from the Phase I/II DIAMOND-01 trial
Roland Walter • 20 Sep 2026
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
8:33
Combination strategies in AML: triplets, targeted therapies and venetoclax resistance
Hima Atluri • 20 Sep 2026
How and when to use oral decitabine in AML
12:38
How and when to use oral decitabine in AML
Gail Roboz • 20 Sep 2026
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
22:07
A new era for AML? Lower-intensity frontline therapy and results from the Phase II PARADIGM trial
Amir Fathi • 20 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals